Biosimilar Antibodies
| Cat.No. | Product Name | Information | Isotype |
|---|---|---|---|
| A2555 | Bivatuzumab (Anti-CD44v6) | Bivatuzumab (Anti-CD44v6) is a humanised monoclonal antibody targeting against CD44v6 that could acts as a sarcoma target for CAR-redirected CIK cells. MW:145.5 KD. | Human IgG1 |
| A2300 | Anti-VEGFR3 / FLT4 | Anti-VEGFR3 / FLT4 is a fully-human monoclonal antibody directed against (VEGFR-3; Flt-4) with antiangiogenic activity. Anti-VEGFR3 / FLT4 also plays a critical role in the embryonic vascular system development. | Human IgG1 |
| A2556 | Ibalizumab (Anti-CD4) | Ibalizumab (Anti-CD4) is a humanised IgG4 monoclonal antibody, targeting C4. It prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research. MW:145.5 KD. | Human IgG4SP |
| A2301 | Icrucumab (Anti-VEGFR1 / FLT1) | Icrucumab (Anti-VEGFR1 / FLT1) is a humanised Anti-VEGFR-1 IgG1 monoclonal antibody, with potential anti-tumour and anti-metastatic agent. It also acts as a therapeutic anti-angiogenic agent in different pathological contexts. | Human IgG1 |
| A2557 | Teplizumab (Anti-CD3e) | Teplizumab (Anti-CD3e) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes. MW:145.5 KD. | Human IgG1 |
| A2302 | Anti-VEGFC | Anti-VEGFC is a fully human monoclonal antibody targeting the human vascular endothelial growth factor C (VEGFC or Flt4 ligand) with potential antiangiogenic activity and lymphangiogenesis. It also prevents metastasis. MW: 145.5 KD. | Human IgG1 |
| A2303 | Anti-VEGFB | Anti-VEGFB (CSL346) is an antibody targeting VEGFA. MW:150 KD. | Human IgG4SP |
| A2559 | Galiximab (Anti-CD28L / CD80) | Galiximab (Anti-CD28L/CD80) is a primatised immunoglobulin G1 (IgG1) lambda monoclonal antibody targeting the CD80 antigen. Galiximab has variable regions that are primatised (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma. MW:145.5 KD. | Human IgG1 |
| A2560 | Anti-CD28 | Anti-CD28 (FR104) is an antibody targeting CD28. MW:145.5 KD. | Human IgG2SA |
| A2305 | Ranibizumab (Anti-VEGFA) | Ranibizumab (Anti-VEGFA) is a recombinant humanised IgG1 monoclonal antibody fragment that inhibits (VEGF-A) and degrades angiogenesis throughout the body and in the eye also interrupts the interaction of VEGF with its receptors, and thus prevents the subsequent growth of new blood vessels. | Human IgG1 |
| A2561 | Ocrelizumab (Anti-CD20) | Ocrelizumab (Anti-CD20) is a recombinant humanised monoclonal IgG1 antibody that selectively targets CD20 antigen present on B-cells. It is used to treat relapsing remitting multiple sclerosis. MW:145.5 KD. | Human IgG1 |
| A2306 | otlertuzumab (Anti-TSPAN26 / CD37) | Otlertuzumab (Anti-TSPAN26 / CD37) is a humanised monoclonal antibody and anti-CD37 protein therapeutic. It is a potent monospecific protein used in treatments of refractory follicular non-Hodgkin lymphoma (FL), mantle cell lymphoma (MCL), or Waldenström's macroglobulinaemia (WM) | Human IgG1 |
| A2562 | Siplizumab (Anti-CD2) | Siplizumab (Anti-CD2) is a humanised IgG1 monoclonal antibody targeting CD2. Siplizumab depletes T cells, decreases T cell activation, inhibits T cell proliferation and enriches naive and bona fide regulatory T cells. MW:145.5 KD. | Human IgG1 |
| A2307 | Tezepelumab (Anti-TSLP) | Tezepelumab (Anti-TSLP) is a potent human IgG2 monoclonal antibody that inhibits the binding of TSLP to the TSLP receptor, and also has potent efficacy and mechanism in asthma. | Human IgG2 |
| A2563 | Tafasitamab (Anti-CD19) | Tafasitamab (Anti-CD19) is an Fc-modified, humanised monoclonal antibody that binds to the human B-cell surface antigen CD19. It is used in combination with allogeneic NK cell therapy in treatment of B-cell non-Hodgkin's lymphoma. MW:145.5 KD. | Human IgG1 |
| A2308 | Anti-TSHR | Anti-TSHR are unconjugated polyclonal antibodies derived from rabbits. Anti-TSHR are pathophysiologic, and also increases their significance in the diagnosis of autoimmune thyroid diseases and Graves' disease. | Human IgG1 |
| A2564 | Inebilizumab (Anti-CD19) | Inebilizumab (Anti-CD19) is a monoclonal antibody targeting CD19 antigen present on B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research. MW:145.5 KD. | Human IgG1 |
| A2309 | Flanvotumab (Anti-TRP1 / TYRP1) | Flanvotumab (Anti-TRP1 / TYRP1) is a monoclonal antibody directed against the melanosomal membrane protein gp75 (or Tyrosinase-Related Protein 1 (TRP1)) with potential immunostimulatory and antineoplastic activities. MW: 145.5 kD. | Human IgG1 |
| A2565 | Anti-CD163 | Anti-CD163 (OR2805) is a human immunoglobulin G1 (IgG1) monoclonal antibody targeting CD163 (scavenger receptor cysteine-rich type 1 protein M130), with potential immunomodulating and antineoplastic activities. It targets and binds to CD163 expressed on immunosuppressive tumor-associated macrophages (TAMs) within the tumor microenvironment (TME), and prevents the binding of CD163 to its ligands. MW:145.5 KD. | Human IgG1 |
| A2566 | Atibuclimab (Anti-CD14) | Atibuclimab (Anti-CD14) is a chimeric monoclonal antibody targeting CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. MW:145.5 KD. | Human IgG4SP |
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.